Differences Between Platelet And Coagulation Disorders
Bleeding Patterns And Clinical Presentation
| Clinical Feature | Platelet Disorder | Coagulation Disorder |
|---|
| Site Of Bleeding | Skin, mucous membranes (mucosal bleeds: epistaxis, oral, gastrointestinal tract) | Soft tissues, joints, muscles (deep bleeds) |
| Petechiae | Yes | No |
| Ecchymoses | Small, superficial | Large, deep |
| Hemarthrosis And Muscle Bleeding | Extremely rare | Common |
| Bleeding After Minor Trauma | Yes | No |
| Bleeding After Surgery | Immediate; usually mild | Delayed (1-2 days); often severe |
Pathophysiology Of Hemostasis
Cellular Phase
- Involves platelets and vascular wall.
- Culminates in generation of hemostatic plug.
- Requires von Willebrand factor to tether platelets to injured subendothelium.
- Defects cause immediate mucocutaneous bleeding.
Fluid Phase
- Involves plasma proteins.
- Multiple-step zymogen pathway leads to thrombin generation.
- Extrinsic pathway serves as primary initiating pathway.
- Intrinsic system functions as regulatory amplification loop.
- Thrombin induces formation of insoluble fibrin clot.
- Fibrinolytic mechanisms limit clot propagation.
- Defects prevent stabilization of platelet plug, causing delayed deep bleeding.
Etiological Classification
Platelet Disorders
- Immune Destruction: Immune thrombocytopenic purpura (ITP) features autoantibodies against platelet glycoproteins.
- Microangiopathic Consumption: Hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, disseminated intravascular coagulation.
- Production Defects: Congenital amegakaryocytic thrombocytopenia, aplastic anemia, Fanconi anemia.
- Qualitative Inherited Defects: Glanzmann thrombasthenia (abnormal glycoprotein IIb/IIIa), Bernard-Soulier syndrome (abnormal glycoprotein Ib).
- Medications: Aspirin, valproate, penicillins.
Coagulation Disorders
- Inherited Deficiencies: Hemophilia A (factor VIII), Hemophilia B (factor IX), von Willebrand disease.
- Acquired Deficiencies: Liver disease impairs synthesis of procoagulant factors.
- Vitamin K Deficiency: Impairs carboxylation of factors II, VII, IX, X.
- Consumption: Disseminated intravascular coagulation depletes multiple clotting factors simultaneously.
- Acquired Inhibitors: Autoantibodies target specific coagulation factors.
Diagnostic Evaluation
Primary Screening Tests
- Complete Hemogram: Evaluates platelet count, assesses red cell morphology for microangiopathy.
- Bleeding Time: Prolonged if platelet count falls below 100,000/μL or in functional defects; lacks reproducibility.
- Prothrombin Time (PT): Evaluates extrinsic and common pathways.
- Activated Partial Thromboplastin Time (aPTT): Evaluates intrinsic and common pathways.
- Thrombin Time (TT): Detects hypofibrinogenemia or dysfibrinogenemia.
Advanced Coagulation And Platelet Assays
- Mixing Studies: Differentiate factor deficiency (corrects) from acquired inhibitors (fails to correct).
- Platelet Aggregation Studies: Replace bleeding time; identify specific functional defects (e.g., absent ristocetin response in Bernard-Soulier).
- Specific Factor Assays: Quantify functional activity of individual coagulation proteins.
- Von Willebrand Panel: Includes von Willebrand antigen, ristocetin cofactor activity, factor VIII assay.
Management Strategies
Platelet Disorder Interventions
- Immune Thrombocytopenia: Corticosteroids, intravenous immunoglobulin (IVIG).
- Chronic Refractory Disease: Thrombopoietin receptor agonists (eltrombopag, romiplostim).
- Severe Hemorrhage: Platelet transfusions reserved for life-threatening bleeds.
- Functional Defects: Desmopressin (DDAVP) enhances hemostasis in certain storage pool deficiencies.
Coagulation Disorder Interventions
- Factor Replacement: Specific recombinant or plasma-derived concentrates (Factor VIII, Factor IX) for hemophilia.
- Fresh Frozen Plasma (FFP): Replaces multiple factors; treats liver disease coagulopathy or rare factor deficiencies (e.g., Factor V).
- Cryoprecipitate: Concentrated source of fibrinogen, factor VIII, factor XIII, von Willebrand factor.
- Antifibrinolytic Agents: Aminocaproic acid or tranexamic acid controls mucosal hemorrhage.
- Vitamin K: Corrects deficiency-associated coagulopathy.